Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 3/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663935 | 0.95 | TRPV1 (0.49) | TRPV1CNR2CYP2D6ESR1ESR2 | |
| SCHEMBL1664148 | 0.81 | TRPV1 (0.54) | TRPV1ESR1ESR2HDAC1HDAC6 | |
| SCHEMBL1663421 | 0.81 | TRPV1 (0.54) | TRPV1ESR1ESR2HDAC1HDAC6 | |
| SCHEMBL1663914 | 0.80 | TRPV1 (0.50) | TRPV1CYP2D6ESR1ESR2HDAC1 | |
| SCHEMBL1663609 | 0.78 | TRPV1 (0.51) | TRPV1ESR1ESR2HDAC1HDAC6 | |
| SCHEMBL1663283 | 0.77 | TRPV1 (0.50) | TRPV1ESR1ESR2HDAC1HDAC6 | |
| SCHEMBL1663625 | 0.77 | TRPV1 (0.50) | TRPV1ESR1ESR2HDAC1HDAC6 | |
| SCHEMBL1664215 | 0.77 | TRPV1 (0.55) | TRPV1ESR1ESR2ALDH1A1NPSR1 | |
| SCHEMBL1663587 | 0.76 | TRPV1 (0.47) | TRPV1ESR1ESR2HDAC1HDAC6 | |
| SCHEMBL5794688 | 0.76 | CYP2D6 (0.57) | CNR2CYP2D6ALDH1A1NPSR1PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| CN-101356160-A | Trisubstituted quinazolinone derivatives as vanilloid antagonists | JANSSEN PHARMACEUTICA NV (CH) | 2009-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | TRPV1, TRPV3, TRPV5 | TRPV1 1/4885CNR2 27/4885CYP2D6 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.